Thermo Fisher seeks immuno-oncology research grant proposals

By The Science Advisory Board staff writers

June 16, 2021 -- Thermo Fisher Scientific is accepting clinical research project submissions in immuno-oncology for its Oncomine Clinical Research Grant program.

The program funds molecular profiling studies that focus on the effect of immune-based treatments for cancer patients. Chosen research teams will be awarded with up to $200,000 in reagents and general funding.

Since its launch in 2020, the grant has been awarded to eight projects worldwide, supporting research in areas including fusion genes detection in solid cancer and hemato-oncology.

Proposals must be submitted to the program by July 16.

Thermo Fisher Scientific upgrades Quick to Clinic
Thermo Fisher Scientific is showcasing a new version of its Quick to Clinic service for biologic drug developers at the BIO Digital 2021 conference, which...
Thermo Fisher inks U.K. agreement to develop advanced workflows
Thermo Fisher Scientific has signed an agreement with the U.K.'s University of Sheffield to develop advanced workflows for characterizing and monitoring...
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.
Thermo Fisher to open cell center, debut microscope
Thermo Fisher Scientific has announced it will open a cell therapy center with the University of California, San Francisco. The company has also unveiled...
Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter